retatrutide clinical data retatrutide vs Tirzepatide vs Semaglutide Retatrutide (LY-3437943) Market Analysis, 2033:

It is a once-daily weight loss pill manufactured by Eli Lilly that received FDA approval on April 1, 2026

"GLP-1 receptor agonists in the treatment of type 2 diabetes state-of-the-art." Molecular Metabolism , 46, 101102

They invariably claim it's better than Ozempic

Contact the company directly

The practical goal is to reduce avoidable contributors: titrate thoughtfully rather than racing to the highest dose, avoid unnecessarily rapid weight loss, prioritize adequate protein, perform resistance training to preserve lean tissue, and monitor for iron, zinc, vitamin D, vitamin B12, vitamin A, and other deficiencies when intake is substantially reduced